DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
Clinical trial NCT04248569 · RECRUITING
Trial details
- NCT number
- NCT04248569
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-04-20
- Primary completion
- 2029-03-01
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.